Zhaoke Ophthalmology’s TAB014 BLA Accepted by China’s NMPA

An announcement from Zhaoke Ophthalmology Ltd. ( (HK:6622) ) is now available.

Zhaoke Ophthalmology Limited has announced that the National Medical Products Administration of China has accepted its Biologics License Application for TAB014, a treatment for wet age-related macular degeneration (wAMD). This marks the first bevacizumab-based antibody filing for wAMD in China, following successful Phase III clinical trials. The company has secured full control over the development and commercialization of TAB014 in China, Hong Kong, and Macau, through an agreement with TOT BIOPHARM Co., Ltd. The acceptance of this application positions Zhaoke Ophthalmology as a significant player in the rapidly growing wAMD market, which is expected to expand significantly by 2030.

More about Zhaoke Ophthalmology Ltd.

Zhaoke Ophthalmology Limited is a company focused on the ophthalmology industry, primarily developing treatments for eye-related conditions. One of its core products is TAB014, a recombinant humanized anti-VEGF monoclonal antibody for wet age-related macular degeneration (wAMD). The company is involved in clinical research and aims to provide cost-effective therapies for vision loss and blindness, particularly in the Chinese market.

Average Trading Volume: 2,840,948

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.72B

For a thorough assessment of 6622 stock, go to TipRanks’ Stock Analysis page.